Greenwich LifeSciences, Inc. (GLSI) investor relations documents from the company's IR site: 8 press releases. Read in-app with summaries. First-party data.
| Published | Type | Document |
|---|---|---|
| 2026-08-10 | Press release | Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027 |
| 2026-07-22 | Press release | Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom |
| 2026-07-20 | Press release | Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01 |
| 2026-07-16 | Press release | Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01 |
| 2026-07-09 | Press release | Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01 |
| 2026-06-01 | Press release | Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026 |
| 2026-04-23 | Press release | Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026 |
| 2026-04-20 | Press release | Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026 |
GLSI overview · GLSI earnings · GLSI financials · GLSI KPIs · GLSI ownership · GLSI peers · GLSI filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.